Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on precision oncology. The company uses the genetic principle of synthetic lethality to discover and develop cancer therapies, with news centered on its PRMT5 inhibitor program, including vopimetostat, and related oncology combination research.
Recurring updates also cover financial results and business highlights, clinical supply and collaboration activity, investor-conference participation, board and executive appointments, and equity compensation actions under the company’s 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Tango Therapeutics (NASDAQ:TNGX) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and marketable securities totaled $379.8 million as of March 31, 2026, expected to fund operations into 2028.
Net loss was $45.5 million ($0.32/share). Vopimetostat combination trials, TNG456 and multiple 2026 data readouts are key upcoming milestones, alongside new senior leadership hires and board changes.
Tango Therapeutics (NASDAQ: TNGX) announced inducement equity awards effective May 1, 2026 under its 2023 Inducement Plan.
The Compensation Committee granted Mr. Matthew Gall a non‑qualified option for 240,000 shares and 40,000 RSUs, and a new employee an option for 199,650 shares and 33,250 RSUs, at an exercise price of $20.98 per share. Options have a 10‑year term; option vesting: 25% at year one then monthly over three years; RSUs vest in three approximately equal annual installments in May 2027–2029. Awards are subject to the 2023 Inducement Plan and award agreements.
Tango Therapeutics (NASDAQ: TNGX) announced leadership appointments to advance vopimetostat, a selective PRMT5 inhibitor, toward potential regulatory approval in pancreatic cancer. Appointments effective April 15 include Matthew Gall as CFO and Janice Kapty, PhD as SVP, with Yen-Ching Chua joining as Chief Development Operations Officer effective June 1.
The hires add finance, global clinical operations, and portfolio strategy expertise to support late-stage development and anticipated initial combination trial data with Revolution Medicines’ RAS(ON) inhibitors this year.
Tango Therapeutics (NASDAQ: TNGX) announced inducement equity grants effective February 2, 2026 under its 2023 Inducement Plan. The Compensation Committee granted a non-qualified option for 367,500 shares at an exercise price of $11.94 and 60,000 RSUs to a new employee.
Options vest 25% on February 2, 2027 then monthly over 36 months; RSUs vest in three tranches of 20,000 on or about February 1, 2027, February 14, 2028 and February 12, 2029, subject to continued employment.
Tango Therapeutics (NASDAQ: TNGX) reported Q4 and full‑year 2025 results and business highlights on March 5, 2026. Key points: $343.1 million cash as of Dec 31, 2025 with runway into 2028; vopimetostat pivotal 2L pancreatic study start expected in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026. The company announced a clinical supply agreement with Erasca, ongoing Revolution Medicines collaboration, and corporate leadership changes including a new CEO and Chief Regulatory Officer.
Tango Therapeutics (NASDAQ: TNGX) will report Q4 2025 financial results on March 5, 2026 before U.S. market open and will not host a conference call. Management will present at three investor conferences in early March 2026, with live webcasts available on the company’s Investors "Events & Presentations" page.
Replays will be archived on the website for 90 days following each presentation.
Tango Therapeutics (NASDAQ: TNGX) announced that Malte Peters, M.D., President and CEO, will appear in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 2:00 PM EST. The event will be webcast live and a replay will be archived on the company website for 90 days.
Tango Therapeutics (NASDAQ: TNGX) announced a leadership transition effective January 8, 2026: founding CEO Barbara Weber, M.D. will retire as CEO and serve as Executive Chair for 2026 before becoming non-executive chair in 2027. Malte Peters, M.D., a current board member since 2018 with late‑stage development and regulatory experience, is named President and CEO effective immediately. Alexis Borisy will transition to Lead Independent Director. The company reiterated clinical milestones for 2026, including multiple vopimetostat combination trial readouts and monotherapy updates, start of a 2L pancreatic cancer pivotal study, and initial safety/efficacy data for TNG456.
Tango Therapeutics (NASDAQ: TNGX) announced that Sung Lee has been appointed to its Board of Directors effective Jan. 5, 2026. Lee brings over 20 years of finance leadership in biopharma and technology and currently serves as Executive Vice President and Chief Financial Officer at Cytokinetics (role assumed May 2024).
The company highlighted Lee's experience in corporate strategy, investor relations, and finance as supportive for advancing its lead program, vopimetostat, into registrational studies and for growing the organization for late-stage clinical development. Lee's prior roles include CFO at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics, 14 years at Gilead Sciences, and early-career work in tax advisory at PwC. His education includes a bachelor's in economics from UC Irvine and a Master of Business Taxation from USC.
Tango Therapeutics (NASDAQ: TNGX) said CEO Barbara Weber, M.D. will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST / 12:45pm EST.
The presentation will be streamed live via the Investors > Events & Presentations page on the company's website, and a replay will be archived on the website for 90 days after the event.